natgillin/translations-raw huggingface dataset:
Compounds for use of claim 61, wherein the disease, disorder, or condition is a metabolic disease selected from the group consisting of insulin-dependent diabetes mellitus and non-insulin-dependent diabetes mellitus. 
Spojevi za uporabu prema zahtjevu 61, naznačeni time što je bolest, poremećaj ili stanje metabolički poremećaj odabran iz skupine koju čine dijabetes melitus ovisan o inzulinu i dijabetes melitus koji nije ovisan o inzulinu.
Compounds for use of claim 61, wherein the disease, disorder, or condition is a liver disease selected from the group consisting of non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, hepatitis-C virus-induced fibrosis and cirrhosis, and alcoholic fibrosis. 
Spojevi za uporabu prema zahtjevu 61, naznačeni time što je bolest, poremećaj ili stanje bolest jetre odabrana iz skupine koju čine nealkoholna bolest masne jetre, nealkoholni steatohepatitis, fibroza uzrokovana virusom hepatitisa C i ciroza, te alkoholna fibroza.
Compounds for use of claim 61, wherein the disease is cancer selected from the group consisting of glioblastoma, breast cancer, colon cancer, primary and metastatic lung cancer, mesothelioma, osteosarcoma, malignant melanoma, ovarian cancer, cervical cancer, prostate cancer, liver cancer, gastric cancer, metastatic renal cancer, leukemia, and lymphoma. 
Spojevi za uporabu prema zahtjevu 61, naznačeni time što je bolest rak odabran iz skupine koju čine glioblastom, rak dojke, rak debelog crijeva, primarni i metastatski rak pluća, mezoteliom, osteosarkom, maligni melanom, rak jajnika, rak vrata maternice, rak prostate, karcinom jetre, rak želuca, metastatski karcinom bubrega, leukemija i limfom.
Compounds for use of claim 61, wherein the disease is a kidney disease selected from the group consisting of nephoropathy (e.g., diabetic nephropathy), focal segmental glomerulosclerosis, tubulointerstitial fibrosis, postransplant fibrosis, and retroperitoneal fibrosis (Ormond's disease). 
Spojevi za uporabu prema zahtjevu 61, naznačeni time što je bolest bolest bubrega odabrana iz skupine koju čine nefropatija (npr., dijabetička nefropatija), fokalna segmentna glomeruloskleroza, tubulointersticijska fibroza, postransplantacijska fibroza i retroperitonealna fibroza (Ormondova bolest).
Compounds for use of claim 61, wherein the disease is a fibrotic disorder. 
Spojevi za uporabu prema zahtjevu 61, naznačeni time što je bolest fibrotični poremećaj.
Compounds for use of claim 70, wherein the fibrotic disorder is idiopathic pulmonary fibrosis (IPF). 
Spojevi za uporabu prema zahtjevu 70, naznačeni time što je fibrotični poremećaj idiopatska plućna fibroza (IPF).
Compounds for use of claim 61, wherein the disease is a storage disease selected from the group consisting of Gaucher disease, Fabry disease, lysosomal storage disorders, Niemann-Pick disease, nephropatic cysteinosis, and X-linked globotiaosylceramidosis. 
Spojevi za uporabu prema zahtjevu 61, naznačeni time što je bolest bolest nakupljanja odabrana iz skupine koju čine Gaucherova bolest, Fabryjeva bolest, lizosomalni poremećaji nakupljanja, Niemann-Pickova bolest, nefropatska cisteinoza, te X-vezana globotiaosilceramidoza.
creating a patient-specific three-dimensional model of a portion of the one patient based only on the medical images of the one patient; 
kreiranje trodimenzionalnog modela specifičnog za pacijenta dijela tijela pacijenta na osnovu najmanje jednog skupa prvih medicinskih slika;
A base station apparatus for using a plurality of Physical Resource Blocks, PRBs, into which a plurality of subcarriers consecutive in a frequency domain are divided, the base station apparatus comprising: 
Integrirani krug prilagođen za upravljanje postupkom u uređaju baznoj stanici za korištenje pluraliteta blokova fizičkih resursa, PRB-ova, u koje je podijeljen veći broj podnosača koji su uzastopni u frekvencijskoj domeni, postupak sadržeći:
The base station apparatus according to claim 1, wherein the number is the resource block group size. 
Integrirani krug sukladno zahtjevu 1, naznačen time da je broj veličina grupe bloka resursa.
The base station apparatus according to one of claims 1 to 7, wherein said allocating unit is configured to allocate, in the second allocation, PRBs, to which the DVRBs are not mapped, to the mobile station apparatus. 
Integrirani krug sukladno jednom od zahtjeva 1 do 7, naznačen time da su u drugoj dodjeli, PRB-ovi, na koje DVRB-ovi nisu mapirani, dodijeljeni uređaju mobilnoj stanici.
The base station apparatus according to one of claims 1 to 9, wherein said allocating unit is adapted to map, in the second allocation, Localized Virtual Resource Blocks, LVRBs, to PRBs, and to allocate the LVRBs to the mobile station apparatus in units of the RBGs. 
Integrirani krug sukladno jednom od zahtjeva 1 do 9, naznačen time da su u drugoj dodjeli, lokalizirani virtualni blokovi resursa, LVRB-ovi, mapirani na PRB-ove, i LVRB-ovi su dodijeljeni uređaju mobilnoj stanici u jedinicama RBG-a.
The base station apparatus according to one of claims 1 to 12, wherein two of the DVRBs are mapped to two of the PRBs in the same frequency of a subframe, respectively. 
Integrirani krug sukladno jednom od zahtjeva 1 do 12, naznačen time da su dva od DVRB-a mapirana odgovarajuće na dva od PRB-ova na istoj frekvenciji podokvira.
The base station apparatus according to one of claims 1 to 13, wherein DVRBs with nonconsecutive DVRB numbers are mapped to two of the PRBs that are adjacent to each other in the frequency domain. 
Integrirani krug sukladno jednom od zahtjeva 1 do 13, naznačen time da su DVRB-i s ne-uzastopnim DVRB brojevima mapirani na dva od PRB-a koji su susjedni u frekvencijskoj domeni.
The base station apparatus according to one of claims 1 to 14, wherein the gap is the largest of gaps which are integer multiples of a number of consecutive PRBs that form the RBG and which are available depending on system bandwidth. 
Integrirani krug sukladno jednom od zahtjeva 1 do 14, naznačen time da je razmak najveći od razmaka koji su cjelobrojni višekratnici broja uzastopnih PRB-ova koji tvore RBG i koji su dostupni ovisno o propusnosti sustava.
a second layer made of a nonwoven fabric having inside a structure formed by fibers of a polypropylene and polyethylene polymer and thermostable elastomers, where the fibers are perforated and impregnated with a compound that increases a hydrophilic effect and accelerates a body fluid flow that is going to get in contact, towards the inside of the device; 
drugi sloj izrađen od netkanog prediva koji ima unutarnju strukturu oblikovanu vlaknima iz polipropilena ili polietilen polimera i termostabilnih elastomera, kod čega su vlakna perforirana i impregnirana finim praškastim turmalinom koji ima nanometrijsku veličinu da poveća hidrofilno djelovanje i ubrza tok tjelesnog fluida koji dolazi u kontakt, prema unutrašnjosti uloška;
an inner layer made of a chlorine-free super absorbent polymer; and an outer layer opposite to the first layer, the outer layer is a support layer made of a material that allows air flow through it, but that acts as a moisture barrier. 
unutarnji sloj izrađen iz visoko apsorbirajućeg polimera bez klora; i vanjski sloj suprotan prvom sloju, kod čega je vanjski sloj potporni sloj izrađen iz materijala koji dopušta protok zraka kroz njega, ali koji djeluje kao zapreka vlazi.
The sanitary device according to claim 1, wherein the structure of polypropylene fibers and elastomers thermostable impregnated with tourmaline occupies a space on the sanitary device that is within the range of 1/2 to 2/4 with respect to a length and a width of the sanitary device. 
Higijenski uložak prema patentnom zahtjevu 1, naznačen time, da struktura polipropilenskih vlakana i termostabilnih elastomera, impregniranih turmalinom, zauzima prostor na higijenskom ulošku koji je unutar područja od 1/2 do 2/4 s obzirom na duljinu i širinu higijenskog uloška.
The sanitary device in accordance with claim 1, wherein the sanitary device is a surgical use device or a healing device. The use of tourmaline having finely pulverized dust with nanometric size impregnated in fibers for application in surgical use devices, healing devices, or personal hygiene devices. The use according to claim 12, wherein fibers are polypropylene and thermostable elastomers fibers are formed on non-woven fabric. 
Higijenski uložak prema patentnom zahtjevu 1, naznačen time, da higijenski uložak jest uložak za kiruršku primjenu ili uložak za zacjeljivanje. Uporaba turmalina kao fino smrvljenog praha nanometrijske veličine, impregniranog u vlakna, naznačena time, da se u vlaknima primjenjuje u ulošcima za kiruršku primjenu, u ulošcima za zacjeljivanje, ili u ulošcima za osobnu higijenu, kod čega su vlakna polipropilen i vlakna termostabilnih elastomera, a oblikovana su kao netkani materijal.
each of R2, R3, R4 and R5 is independently a hydrogen atom, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, halogen, cyano or hydroxyl, or R2 together with R3 and R4 together with R5 are independently taken together with a carbon atom to which they are attached to form a carbonyl group (C=O); 
svaki od R2, R3, R4 i R5 je neovisno vodikov atom, C1-C6 alkil, C3-C6 cikloalkil, C1-C6 haloalkil, C1-C6 alkoksi, C1-C6 haloalkoksi, halogen, cijano ili hidroksil, ili R2 zajedno s R3 i R4 zajedno s R5 se neovisno uzimaju zajedno s ugljikovim atomom na koji su vezani da tvore karbonilnu skupinu (C=O);
and R19 are taken together with a carbon atom to which they are attached to form a 3-7 membered ring containing members selected from carbon atom and at most 4 heteroatoms independently selected from at most 2 oxygen atoms, at most 2 sulfur atoms, at most 2 nitrogen atoms, and at most 2 silicon atoms, wherein at most 3 carbon atom members may be substituted with oxo or thioxo, a sulfur atom member is independently selected from S(=O)p(=NR35)q, a silicon atom member is independently selected from SiR36R37, and a ring may be optionally substituted with at most 4 substituents independently selected from halogen, cyano, C1-C2 alkyl, C1-C2 haloalkyl, C1-C2 alkoxy or C1-C2 haloalkoxy on a carbon atom member, and cyano, C1-C2 alkyl or C1-C2 alkoxy on a nitrogen atom member; 
i R19 se uzimaju zajedno s ugljikovim atomom na koji su vezani tako da tvore 3-7 člani prsten koji sadrži članove odabrane od ugljikovog atoma i najviše 4 heteroatoma neovisno odabrana od najviše 2 kisikova atoma, najviše 2 sumporova atoma, najviše 2 dušikova atoma, i najviše 2 silicijeva atoma, pri čemu najviše 3 člana ugljikovih atoma mogu biti supstituirani s okso ili tiokso, član sumporov atom je neovisno odabran od S(=O)p(=NR35)q, član silicijev atom je neovisno odabran od SiR36R37, i prsten može biti prema potrebi supstituiran s najviše 4 supstituenata neovisno odabranih od halogena, cijano, C1-C2 alkila, C1-C2 haloalkila, C1-C2 alkoksi ili C1-C2 haloalkoksi na članu atomu ugljika, i cijano, C1-C2 alkil ili C1-C2 alkoksi na članu atomu dušika;
A method of controlling plant disease generated from phytopathogenic microorganism comprising steps of applying the fungicidal composition of Claim 11 to an entire plant or a part thereof or seeds of a plant. 
Postupak kontrole biljne bolesti generirane iz fitopatogenog mikroorganizma naznačen time što obuhvaća korake nanošenja fungicidnog pripravka prema zahtjevu 11 na cijelu biljku ili dio biljke ili sjeme biljke.
A method of producing a compound of formula [1a] comprising a step of reacting a thiazole derivative of formula [2] and a benzene derivative of formula [3] under a presence of an acid or Lewis acid and a solvent: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, G1, X1, X2, X3, X4, T and n are as defined in Claim 1. 
Postupak za proizvodnju spoja formule [1a] naznačen time što obuhvaća korak reakcije tiazolnog derivata formule [2] i benzenskog derivata formule [3] u prisutnosti kiseline ili Lewisove kiseline i otapala: pri čemu R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, G1, X1, X2, X3, X4, T i n su kako je definirano u zahtjevu 1.
A method of producing a compound of formula [lb] comprising a step of reacting a thiazole derivative of formula [4] and a benzene derivative of formula [3] under a presence of an acid or Lewis acid and a solvent: wherein R1, R2, R3, R4, R5, R6, R13, R14, R15, R16, R17, E, G2, X1, X2, X3, X4 T and n are as defined in Claim 1. 
Postupak za proizvodnju spoja formule [1b] naznačen time što obuhvaća korak reakcije tiazolnog derivata formule [4] i benzenskog derivata formule [3] u prisutnosti kiseline ili Lewisove kiseline i otapala: pri čemu, R1, R2, R3, R4, R5, R6, R13, R14, R15, R16, R17, E, G2, X1, X2, X3, X4, T i n su kako je definirano u zahtjevu 1.
A method of producing a compound of formula [1c] comprising a step of reacting a thiazole derivative of formula [5] and a benzene derivative of formula [3] under a presence of an acid or Lewis acid and a solvent: wherein R1, R2, R3, R4, R5, R6, R11, R12, R18, R19, G3, X1, X2, X3, X4, Z, T and n are as defined in Claim 1. 
Postupak za proizvodnju spoja formule [1c] naznačen time što obuhvaća korak reakcije tiazolnog derivata formule [5] i benzenskog derivata formule [3] u prisutnosti kiseline ili Lewisove kiseline i otapala: pri čemu R1, R2, R3, R4, R5, R6, R11, R12, R18, R19, G3, X1, X2, X3, X4, Z, T i n su kako je definirano u zahtjevu 1.
A method of producing a compound of formula [1d] comprising a step of reacting a thiazole derivative of formula [6] and a benzene derivative of formula [3] under a presence of an acid or Lewis acid and a solvent: wherein R1, R2, R3, R4, R5, R6, R20, R21, R22, R23, R24, G4, X1, X2, X3, X4, T and n are as defined in Claim 1. 
Postupak za proizvodnju spoja formule [1d] naznačen time što sadrži korak reakcije tiazolnog derivata formule [6] i benzenskog derivata formule [3] u prisutnosti kiseline ili Lewisove kiseline i otapala: pri čemu R1, R2, R3, R4, R5, R6, R20, R21, R22, R23, R24, G4, X1, X2, X3, X4, T i n su kako je definirano u zahtjevu 1.
A method of producing a compound of formula [1d] comprising a step of reacting a substituted 11 membered compound of formula [14] and formula [15] under a presence of a base and a solvent: wherein R1, R2, R3, R4, R5, R6, R20, R21, R22, R23, R24, G4, X1, X2, X3, X4, T and n are as defined in Claim 1. 
Postupak za proizvodnju spoja formule [1d] naznačen time što sadrži korak reakcije supstituiranog 11-eročlanog spoja formule [14] i formule [15] u prisutnosti baze i otapala: pri čemu R1, R2, R3, R4, R5, R6, R20, R21, R22, R23, R24, G4, X1, X2, X3, X4, T i n su kako je definirano u zahtjevu 1.
A method of producing a compound of formula [1d] comprising a step of reacting a substituted 11 membered compound of formula [16] and formula [17] or formula [18] under a presence of a base and a solvent: wherein R1, R2, R3, R4, R5, R6, R20, R21, R22, R23, R24, R40, R41, G4, X1, X2, X3, X4, T and n are as defined in Claim 1, and G5 is an oxygen atom or a sulfur atom, and L3 is a leaving group. 
Postupak za proizvodnju spoja formule [1d] naznačen time što sadrži korak reakcije supstituiranog 11-eročlanog spoja formule [16] i formule [17] ili formule [18] u prisutnosti baze i otapala: pri čemu R1, R2, R3, R4, R5, R6, R20, R21, R22, R23, R24, R40, R41, G4, X1, X2, X3, X4, T i n su kako je definirano u zahtjevu 1, i G5 je kisikov atom ili sumporov atom, i L3 je odlazeća skupina.
comparing measured autoimmune reactivity values with standard data obtained from glaucoma patients and optionally additionally from healthy individuals, to determine a glaucoma score and 
uspoređivanje izmjerenih autoimunoloških reaktivnih vrijednosti sa standardnim podacima dobivenim od pacijenta s glaukomom i prema potrebi dodatno od zdravih pojedinaca, u svrhu određivanja proračuna za glaukom, te
The method for the diagnosis of glaucoma according to claim 1 or 2, wherein a partially purified ocular antigen comprises said ocular antigen in an amount of at least 70% per weight of total protein. 
Postupak dijagnoze glaukoma prema zahtjevu 1 ili 2, naznačen time, da djelomično pročišćen očni antigen obuhvaća navedeni očni antigen u količini koja iznosi najmanje 70 težinskih % od ukupnog proteina.
The method for the diagnosis of glaucoma according to anyone of claims 1 to 3 wherein at least one sample comprises at least 1 at least partially purified ocular antigen of the following ocular antigens of Group 2: albumin,, annexin I-IV,, brain derived neurotrophic factor (BDNF), calreticulin, cardiolipin,, beta-S-crystalline, gamma-crystalline, DNA topoisomerase 1, fibronectin,, insulin, jo-1, lysozyme, myelin oligodrendrocyte glycoprotein (MOG), myoglobin, neurotrophin 3, neurotrophin 4, neurotrophin 5, peroxide-dismutase, 3-phosphoserin, pre-albumin, protein kinase C inhibitor, protein kinase C, superoxide dismutase, alpha-synuclein, thyreoglobulin, transferrin, transthyretin, topoisomerase-inhibitor, ubiquitin, vascular endothelial growth factor (VEGF). 
Postupak dijagnoze glaukoma prema bilo kojem od zahtjeva 1 do 3, naznačen time, da najmanje jedan uzorak obuhvaća najmanje jedan barem djelomično pročišćeni očni antigen od sljedećih očnih antigena iz Skupine 2: albumin, aneksin I-IV, BDNF (neurotrofni faktor izveden iz mozga), kalretikulin, kardiolipin, beta-S-kristalin, gama-kristalin, DNA-topoizomeraza 1, fibronektin, inzulin, jo-1, lizozim, mijelin-oligodrendrocitni glikoprotein (MOG), mioglobin, neurotrofin 3, neurotrofin 4, neurotrofin 5, peroksidna dismutaza, 3-fosfoserin, pre-albumin, inhibitor proteinske kinaze C, proteinska kinaza C, superoksidna dismutaza, alfa-sinuklein, tireoglobulin, transferin, transtiretin, inhibitor topoizomeraze, ubikvitin, vaskularni endotelijski faktor rasta (VEGF).
The method for the diagnosis of glaucoma according to anyone of claims 1 to 3 wherein at least one sample of at least partially purified ocular antigens comprises at least 1 of the following ocular antigens albumin, alpha-1-antitrypsin, annexin I-IV, annexin V, brain derived neurotrophic factor (BDNF), calreticulin, cardiolipin, beta-L-crystalline, beta-S-crystalline, gamma-crystalline, DNA topoisomerase 1, fibronectin, heat shock protein HSP10 (=chaperonin), insulin, jo-1, lysozyme, myelin oligodrendrocyte glycoprotein (MOG), myoglobin, neurotrophin 3, neurotrophin 4, neurotrophin 5, peroxide-dismutase, 3-phosphoserin, pre-albumin, protein kinase C inhibitor, protein kinase C, superoxide dismutase, alpha-synuclein, thyreoglobulin, transferrin,, topoisomerase-inhibitor, ubiquitin. 
Postupak dijagnoze glaukoma prema bilo kojem od zahtjeva 1 do 3, naznačen time, da najmanje jedan uzorak od barem djelomično pročišćenih očnih antigena obuhvaća najmanje jedan od sljedećih očnih antigena: albumin, alfa-1-antitripsin, aneksin I-IV, aneksin V, BDNF (neurotrofni faktor izveden iz mozga), kalretikulin, kardiolipin, beta-L-kristalin, beta-S-kristalin, gama-kristalin, DNA-topoizomeraza 1, fibronektin, protein toplinskog šoka HSP10 (=šaperonin), inzulin, jo-1, lizozim, mijelin-oligodrendrocitni glikoprotein (MOG), mioglobin, neurotrofin 3, neurotrofin 4, neurotrofin 5, peroksidna dismutaza, 3-fosfoserin, pre-albumin, inhibitor proteinske kinaze C, proteinska kinaza C, superoksidna dismutaza, alfa-sinuklein, tireoglobulin, transferin, inhibitor topoizomeraze, ubikvitin.
The method for the diagnosis of glaucoma according to anyone of claims 1 to 3 wherein the at least two samples of at least partially purified ocular antigens comprises at least 1 of the following ocular antigens: alpha-1-antitrypsin, annexin I-IV, annexin V, calreticulin, beta-L-crystalline, beta-S-crystalline, gamma-crystalline, heat shock protein HSP10 (=chaperonin), insulin, jo-1, myelin, peroxide-dismutase, pre-albumin, protein kinase C inhibitor, protein kinase C, superoxide dismutase, alpha-synuclein, transferrin, transthyretin, ubiquitin. 
Postupak dijagnoze glaukoma prema bilo kojem od zahtjeva 1 do 3, naznačen time, da najmanje dva uzorka od barem djelomično pročišćenih očnih antigena, obuhvaćaju najmanje jedan od sljedećih očnih antigena: alfa-1-antitripsin, aneksin I-IV, aneksin V, kalretikulin, beta-L-kristalin, beta-S-kristalin, gama-kristalin, protein toplinskog šoka HSP10 (=šaperonin), inzulin, jo-1, mijelin, peroksidna dismutaza, pre-albumin, inhibitor proteinske kinaze C, proteinska kinaza C, superoksidna dismutaza, alfa-sinuklein, transferin, transtiretin, ubikvitin.
The method according to anyone of claim 1 to 7, wherein the sample or the samples comprising at least two partially purified ocular antigens are carried on an antigen carrying element, and in particular wherein the body fluid is reacted with antigens on a microarray chip, on a lateral flow test strip, on a microfluidic chip or in other fluidic or bead based assays. 
Postupak prema bilo kojem od zahtjeva 1 do 7, naznačen time, da se uzorak ili uzorci koji obuhvaća/ju najmanje dva djelomično pročišćena očna antigena, prenose na antigenskom nosivom elementu, te time, da se posebice tjelesni fluid dovodi u reakciju s antigenima na mikrotestnom čipu, na testnoj traci bočnog protoka, mikrofluidnom čipu ili na ostalim vrstama testiranja na bazi fluida ili zrnaca.
A compound having the formula: or a pharmaceutically acceptable salt thereof, wherein Ring A is Ring B is wherein Ring B is optionally substituted with up to 4 fluorine atoms, up to two OH or up to two C1-4alkyl which is optionally substituted with up to 3 fluorine atoms, up to two OH, or up to two OC1-2alkyl groups; 
Spoj formule: ili njegova farmaceutski prihvatljiva sol, gdje je prsten A ili je prsten B ili gdje je prsten B izborno supstituiran sa do 4 atoma fluora, do dva OH ili do dva C1-4alkila koji je izborno supstituiran sa do 3 atoma fluora, do dvije OH ili do dvije OC1-2alkil grupe;
The compound of claim 1, selected from the following compounds, or a pharmaceutically acceptable salt thereof: 
Spoj prema patentnom zahtjevu 1, izabran od sljedećih spojeva, ili njegova farmaceutski prihvatljiva sol:
A compound selected from the following compounds, or a pharmaceutically acceptable salt thereof: 
Spoj izabran od sljedećih spojeva, ili njegova farmaceutski prihvatljiva sol:
potentiating a therapeutic regimen for the treatment of cancer in a patient. 
stimulaciji terapeutskog režima za liječenje raka kod pacijenta.
represents an amino acid residue with a functionalized -NH2 side chain group, selected from the group consisting of Lys, Orn, Dab, or Dap, wherein the -NH2 side chain group is functionalized by -Z-C(O)-R5, wherein Z represents a linker in all stereoisomeric forms and R5 is a moiety comprising up to 50 carbon atoms and heteroatoms selected from N and O, 
predstavlja aminokiselinski ostatak s funkcionaliziranom skupinom -NH2 bočnog lanca, odabranu iz skupine koju čine Lys, Orn, Dab, ili Dap, pri čemu je skupina -NH2 bočnog lanca funkcionalizirana pomoću -Z-C(O)-R5, pri čemu Z predstavlja premosnicu u svim stereoizomernim oblicima i je skupina koja sadrži do 50 ugljikovih atoma i heteroatome odabrane od N i O,
represents Lys wherein the -NH2 side chain group is functionalized with a group -Z-C(O)R5, wherein Z represents a group selected from γE, γE-γE, AEEAc-AEEAc-γE and AEEAc-AEEAc-AEEAc and R5 represents a group selected from pentadecanyl, heptadecanyl or 16-carboxy-hexadecanyl . 
predstavlja Lys pri čemu je skupina -NH2 bočnog lanca funkcionalizirana sa skupinom -Z-C(O)R5, pri čemu Z predstavlja skupinu odabranu od γE, γE-γE, AEEAc-AEEAc-γE i AEEAc-AEEAc-AEEAc i predstavlja skupinu odabranu od pentadekanila ili heptadekanila ili 16-karboksi-heksadekanila.
represents Lys wherein the -NH2 side chain group is functionalized with a group -Z-C(O)R5, wherein Z represents a group selected from γE, γE-γE, AEEAc-AEEAc-γE and AEEAc-AEEAc-AEEAc and R5 represents a group selected from pentadecanyl or heptadecanyl. 
predstavlja Lys pri čemu je skupina -NH2 bočnog lanca funkcionalizirana sa skupinom -Z-C(O)R5, pri čemu Z predstavlja skupinu odabranu od γE, γE-γE, AEEAc-AEEAc-γE i AEEAc-AEEAc-AEEAc i predstavlja skupinu odabranu od pentadekanila ili heptadekanila.